U.S. Personal Products Stock News

Constellium FY 2025 Results: Revenue Steady, Earnings Volatile Constellium (CSTM) just posted another quarter of mixed numbers, with Q3 2025 revenue at US$2.2b, basic EPS of US$0.63 and net income of US$88m. The latest trailing twelve month figures show revenue of about US$8.0b and EPS of US$0.80 alongside a net margin of 1.4% compared to 1.8% the prior year. Over recent quarters, the company has seen revenue move from US$1.8b in Q3 2024 to US$2.2b in Q3 2025. Quarterly EPS has swung from a...

If you are wondering whether Texas Pacific Land is attractively priced or simply expensive for what you get, you are in the right place to unpack what the current share price might be implying. The stock closed at US$440.71, with returns of 6.6% over 7 days, 30.6% over 30 days, 47.9% year to date, while the 1 year return stands at a 5.3% decline and the 3 year and 5 year returns are 129.4% and 268.9% respectively. Recent news around Texas Pacific Land has focused on its position within the...

Kontoor Brands (NYSE:KTB) has adopted an Executive Severance Plan, formalizing protections for senior leadership in certain termination scenarios. The board also approved a quarterly dividend, continuing the return of capital to shareholders. These moves come as the company’s shares trade at $67.85, with a mixed return profile across different time frames. Kontoor Brands is pairing governance changes with ongoing shareholder payouts at a time when the stock has a varied track record...

Why CureVac's latest trial milestone matters for shareholders CureVac (CVAC) has completed a Phase 1 clinical study for its CVGBM mRNA based brain cancer vaccine in patients with surgically resected glioblastoma or astrocytoma, marking a key early checkpoint for its oncology pipeline. See our latest analysis for CureVac. The completion of the CVGBM Phase 1 study comes after a sharp 14.32% 1 day share price decline and a 19.18% 7 day share price return. However, CureVac’s year to date share...

In February 2026, Parsons Corporation reported fourth-quarter and full-year 2025 results showing lower sales but slightly higher net income year-on-year, while also issuing 2026 revenue guidance of US$6.5 billion to US$6.8 billion and securing several new U.S. defense and security contracts, including a US$125 million Army research award and a US$91 million State Department security extension. Shortly after these mixed results and contract wins, Parsons’ Sealing Technologies unit received an...

Jones Lang LaSalle (JLL) has put up a busy FY 2025 so far, with Q3 revenue at US$6.5b and basic EPS of US$4.71, alongside trailing 12 month revenue of US$25.3b and EPS of US$13.31 that captures the broader earnings cycle. Over recent quarters the company has seen revenue move from US$5.7b and EPS of US$1.17 in Q1 2025 to US$6.3b and EPS of US$2.37 in Q2, and then to US$6.5b and EPS of US$4.71 in Q3, with a 32.1% earnings increase over the past year setting the backdrop for a business where...

Halozyme Therapeutics (HALO) closed out FY 2025 with fourth quarter revenue of US$451.8 million and a basic EPS loss of US$1.20, compared with Q4 2024 revenue of US$298.0 million and basic EPS of US$1.08. Over the past year, the company has seen quarterly revenue move from US$290.1 million in Q3 2024 to US$354.3 million in Q3 2025, while basic EPS shifted from US$1.08 to US$1.49 over the same quarters, creating a mixed picture for margins as investors digest the latest numbers. See our full...

Glaukos (GKOS) has just posted its FY 2025 numbers with Q4 revenue of US$143.1 million and a basic EPS loss of US$2.32, alongside a trailing twelve month revenue line of US$507.4 million and a basic EPS loss of US$3.28. Over recent quarters, the company has seen revenue move from US$96.7 million in Q3 2024 to US$105.5 million in Q4 2024 and then to US$143.1 million in Q4 2025, while quarterly basic EPS losses shifted from US$0.39 in Q3 2024 to US$0.60 in Q4 2024 and US$2.32 in Q4 2025. For...

AtriCure (ATRC) just posted its FY 2025 numbers with Q4 revenue of US$140.5 million and basic EPS of US$0.04 on net income of US$1.8 million, while on a trailing twelve month basis the company remains loss making with basic EPS at US$0.24 and net income of US$11.4 million. The company has seen quarterly revenue move from US$124.3 million in Q4 2024 to US$140.5 million in Q4 2025. Over the same periods, basic EPS shifted from a loss of US$0.33 to a small profit of US$0.04. This sets up a story...

Entegris (ENTG) is back in focus after fourth quarter results topped analyst forecasts. Management pointed to strength in advanced node semiconductor applications and solid demand for CMP consumables and liquid filtration products. See our latest analysis for Entegris. At a share price of US$131.89, Entegris has logged a 91.7% 90 day share price return and a 47.26% year to date share price return. The 1 year total shareholder return of 22.65% points to momentum that has recently...

Comparor has announced the launch of its AI-powered shopping assistant, a tool designed to streamline the online shopping process by offering instant product recommendations and real-time price comparisons across multiple retailers. This solution leverages artificial intelligence to process natural language requests and deliver optimized shopping options, helping users save time and make more informed purchasing decisions. As an emerging trend in e-commerce, AI-enabled tools like Comparor’s...

Artivion, Inc.'s ( NYSE:AORT ) earnings announcement last week was disappointing for investors, despite the decent...

Investors signalled that they were pleased with Cognex Corporation's ( NASDAQ:CGNX ) most recent earnings report. This...

W. R. Berkley Corporation ( NYSE:WRB ) is about to trade ex-dividend in the next three days. The ex-dividend date is...

It looks like Johnson & Johnson ( NYSE:JNJ ) is about to go ex-dividend in the next 4 days. The ex-dividend date occurs...

Andersons (ANDE) has just wrapped up FY 2025 with fourth quarter revenue of US$2.5 billion, basic EPS of US$1.98 and net income of US$67.4 million. Trailing twelve month revenue came in at about US$11.0 billion with EPS of US$2.81. Over recent quarters the company has seen quarterly revenue move between US$2.5 billion and US$3.1 billion, with EPS ranging from close to flat at US$0.01 in Q1 2025 to US$1.98 in Q4. This creates a backdrop where modest net profit margins and small shifts in...

Avient Corporation's ( NYSE:AVNT ) recent soft profit numbers didn't appear to worry shareholders, as the stock price...

Even though DexCom, Inc.'s ( NASDAQ:DXCM ) recent earnings release was robust, the market didn't seem to notice. Our...

As February 2026 begins, U.S. stock markets have shown resilience with major indices like the Dow Jones and S&P 500 ending sharply higher, buoyed by positive economic indicators such as an unexpected expansion in factory activity. In this dynamic environment, small-cap stocks present intriguing opportunities for investors seeking value and growth potential, especially when insider actions suggest confidence in a company's prospects amidst broader market optimism.

As February begins, the U.S. stock market has shown strength with major indices like the Dow Jones and S&P 500 posting significant gains, signaling a positive start to the month despite ongoing economic uncertainties and geopolitical developments. In this environment, high-growth tech stocks in the U.S. market continue to attract attention for their potential to leverage technological advancements and shifting consumer demands, making them noteworthy considerations for investors looking to...

As February 2026 begins, the U.S. stock market shows a robust start with major indices like the Dow Jones Industrial Average and S&P 500 posting significant gains. In this environment of renewed optimism, identifying stocks that may be trading below their estimated value can offer intriguing opportunities for investors looking to capitalize on potential growth amid favorable market conditions.

The market was pleased with the recent earnings report from Insight Enterprises, Inc. ( NASDAQ:NSIT ), despite the...

Global decarbonization policies and subsidies are major drivers of the hydrogen infrastructure market, fostering demand for pipelines, storage, and refueling networks. Key initiatives like the US Inflation Reduction Act and EU plans such as REPowerEU are creating a policy "floor" that lowers investment risks and encourages the advancement of hydrogen infrastructure as part of the broader energy transition. This growing focus on building large-scale hydrogen infrastructure is supported by...

As February begins, U.S. stock markets are showing strong momentum, with major indexes like the Dow Jones Industrial Average and S&P 500 posting significant gains. In this environment of market optimism, investors often look for growth companies with high insider ownership as an indicator of confidence and potential resilience amidst economic shifts.